Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

571P - Preclinical evaluation of FAP-2286, a peptide-targeted radionuclide therapy (PTRT) to fibroblast activation protein alpha (FAP)

Date

17 Sep 2020

Session

E-Poster Display

Presenters

Dirk Zboralski

Citation

Annals of Oncology (2020) 31 (suppl_4): S462-S504. 10.1016/annonc/annonc271

Authors

D. Zboralski1, F. Osterkamp2, A.D. Simmons3, A. Bredenbeck4, A. Schumann4, M. Paschke5, N. Beindorff6, A. Mohan7, M. Nguyen3, J. Xiao8, T.C. Harding3, A. Hoehne9, U. Reineke10, C. Smerling11

Author affiliations

  • 1 Assay Unit, 3B Pharmaceuticals GmbH, 12489 - Berlin/DE
  • 2 Chemistry & Analytics, 3B Pharmaceuticals GmbH, D-12489 - Berlin/DE
  • 3 Translational Medicine, Clovis Oncology, Inc., 80301 - Boulder/US
  • 4 Nuclear Medicine, 3B Pharmaceuticals GmbH, D-12489 - Berlin/DE
  • 5 Biology & Assay Development, 3B Pharmaceuticals GmbH, D-12489 - Berlin/DE
  • 6 Berlin Experimental Radionuclide Imaging Center (beric), Charité - Universitaetsmedizin Berlin, 13353 - Berlin/DE
  • 7 Department Of Nuclear Medicine, Charité - Universitaetsmedizin Berlin, 10117 - Berlin/DE
  • 8 Clinical Pharmacology And Dmpk, Clovis Oncology, Inc., 80301 - Boulder/US
  • 9 Radiopharmaceutical Technologies, 3B Pharmaceuticals GmbH, D-12489 - Berlin/DE
  • 10 Managing Director, 3B Pharmaceuticals GmbH, D-12489 - Berlin/DE
  • 11 Nuclear Medicine And Imaging, 3B Pharmaceuticals GmbH, D-12489 - Berlin/DE
More

Resources

Abstract 571P

Background

FAP is a membrane bound protease that has limited expression in normal adult tissues but is highly expressed on cancer associated fibroblasts (CAFs), which are abundant in most tumours. FAP-2286 is a conjugate of a FAP-binding peptide coupled to a radionuclide chelator (DOTA) for use as a potential PTRT for imaging and therapeutic applications. The potency, selectivity, and efficacy of FAP-2286 were evaluated in vitro and in vivo.

Methods

Immunohistochemistry was performed using FFPE tissue specimens. FAP-2286 and its metal complexes were evaluated in in vitro biochemical and cellular assays and in vivo biodistribution, imaging, and efficacy studies.

Results

Immunohistochemistry confirmed high levels of FAP expression, predominantly in CAFs, in multiple tumour types including pancreatic, breast, and sarcoma. In contrast, FAP expression in normal tissues was limited. FAP-2286 and its metal complexes had potent affinity to human FAP protein (KD, 0.4–1.4 nM). In cellular assays, FAP-2286 showed effective binding (IC50, 1.65–3.4 nM) to FAP expressing WI-38 fibroblasts. FAP-2286 inhibited FAP protease activity (IC50, 1.6–3.2 nM), whereas limited off target activity was seen against closely related family members. In vivo biodistribution (by SPECT/CT) in mice after IV injection showed rapid uptake of 111In- and 177Lu-labelled FAP-2286 in FAP-positive tumours that was maintained for ≥120 hours, limited background in normal tissues, and a renal clearance mechanism. FAP-2286 labelled with the therapeutic β-particle emitting radionuclide 177Lu, at a specific activity of 30 MBq/nmol (low-dose group) or 60 MBq/nmol (high-dose group), had potent anti-tumour activity in FAP expressing HEK-293 xenografts after a single IV dose: tumour growth inhibition at day 14 posttreatment was 112% and 115%, respectively, with no significant weight loss.

Conclusions

In preclinical models, FAP-2286 has a compelling profile for PTRT, including high tumour uptake and retention, and potent efficacy in FAP-positive tumours. IND-enabling nonclinical work is ongoing; clinical studies in a broad spectrum of FAP-positive cancers are planned.

Clinical trial identification

Editorial acknowledgement

Editorial support funded by Clovis Oncology was provided by Frederique H. Evans, MBS, of Ashfield Healthcare Communications.

Legal entity responsible for the study

Clovis Oncology, Inc., 3B Pharmaceuticals GmbH.

Funding

Clovis Oncology, Inc., 3B Pharmaceuticals GmbH.

Disclosure

D. Zboralski: Shareholder/Stockholder/Stock options, Full/Part-time employment: 3B Pharmaceuticals GmbH. F. Osterkamp: Shareholder/Stockholder/Stock options, Full/Part-time employment: 3B Pharmaceuticals GmbH . A.D. Simmons: Shareholder/Stockholder/Stock options, Full/Part-time employment: Clovis Oncology. A. Bredenbeck: Shareholder/Stockholder/Stock options, Full/Part-time employment: 3B Pharmaceuticals GmbH. A. Schumann: Shareholder/Stockholder/Stock options, Full/Part-time employment: 3B Pharmaceuticals GmbH. M. Paschke: Shareholder/Stockholder/Stock options, Full/Part-time employment: 3B Pharmaceuticals GmbH . M. Nguyen: Shareholder/Stockholder/Stock options, Full/Part-time employment: Clovis Oncology. J. Xiao: Shareholder/Stockholder/Stock options, Full/Part-time employment: Clovis Oncology. T.C. Harding: Shareholder/Stockholder/Stock options, Full/Part-time employment: Clovis Oncology. A. Hoehne: Shareholder/Stockholder/Stock options, Full/Part-time employment: 3B Pharmaceuticals GmbH. U. Reineke: Shareholder/Stockholder/Stock options, Full/Part-time employment: 3B Pharmaceuticals GmbH. C. Smerling: Shareholder/Stockholder/Stock options, Full/Part-time employment: 3B Pharmaceuticals GmbH . All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings